CALR and neoplasm: The combined use of chloroquine and bortezomib increases at the same time C/EBP-β LIP and NO levels: this condition restores the ER-dependent/CHOP-mediated apoptosis, down-regulates Pgp expression and activity, increases CRT expression and translocation to the plasma-membrane, re-activates the DC/CD8+T-lymphocyte response against the tumor upon doxorubicin treatment (Fig. 10).